<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Terapia dirigida &#8211; Grupo TTD</title>
	<atom:link href="https://grupottd.org/tag/terapia-dirigida/feed/" rel="self" type="application/rss+xml" />
	<link>https://grupottd.org</link>
	<description>Grupo de Tratamiento de los Tumores Digestivos</description>
	<lastBuildDate>Fri, 31 Jul 2026 12:22:36 +0000</lastBuildDate>
	<language>es</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.5</generator>

<image>
	<url>https://grupottd.org/wp-content/uploads/2026/03/cropped-Logo-TTD-favicon-32x32.png</url>
	<title>Terapia dirigida &#8211; Grupo TTD</title>
	<link>https://grupottd.org</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>ASCO 2026: Avances en Cáncer de Páncreas</title>
		<link>https://grupottd.org/asco-2026-avances-en-cancer-de-pancreas/</link>
					<comments>https://grupottd.org/asco-2026-avances-en-cancer-de-pancreas/#respond</comments>
		
		<dc:creator><![CDATA[Susana Rodríguez]]></dc:creator>
		<pubDate>Fri, 31 Jul 2026 12:22:34 +0000</pubDate>
				<category><![CDATA[Artículos comentados]]></category>
		<category><![CDATA[ASCO 2026]]></category>
		<category><![CDATA[Cáncer de páncreas]]></category>
		<category><![CDATA[Daraxonrasib]]></category>
		<category><![CDATA[Inhibidor RAS multiselectivo]]></category>
		<category><![CDATA[KRAS]]></category>
		<category><![CDATA[NEJM]]></category>
		<category><![CDATA[Oncología de precisión]]></category>
		<category><![CDATA[PDAC]]></category>
		<category><![CDATA[RASolute 302]]></category>
		<category><![CDATA[Segunda línea]]></category>
		<category><![CDATA[Supervivencia global]]></category>
		<category><![CDATA[Terapia dirigida]]></category>
		<guid isPermaLink="false">https://grupottd.org/?p=13507</guid>

					<description><![CDATA[El ensayo fase III RASolute 302 evalúa daraxonrasib frente a quimioterapia en 500 pacientes con cáncer de páncreas metastásico previamente tratado y muestra resultados sin precedentes: en la población con mutación RAS G12 (91,8%), el fármaco duplicó la supervivencia global (13,2 vs 6,6 meses; HR 0,40; p<0,001), mejoró la SLP (7,3 vs 3,5 meses; HR 0,45) y triplicó las respuestas (33,2% vs 11,8%). También retrasó el deterioro clínico por dolor. Su perfil de seguridad fue favorable, con eventos leves (rash, diarrea) y menor tasa de interrupción (1,2% vs 11,2%), aunque se registró un caso de neumonitis letal.

Conclusiones: 
• Eficacia histórica: Daraxonrasib duplica la SG (13,2 vs 6,6 m), mejora la SLP y triplica respuestas en RAS G12. 
• Reducción del 60% del riesgo de muerte (HR 0,40). 
• Calidad de vida: Retrasa el deterioro clínico por dolor 
• Seguridad: Perfil favorable (rash/diarrea) y baja interrupción (1,2% vs 11,2%). • Impacto: Nuevo estándar en 2ª línea.]]></description>
			<style id="elementor-post-13507">.elementor-13507 .elementor-element.elementor-element-3ce7a18b{--display:flex;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-13507 .elementor-element.elementor-element-658f317a > .elementor-widget-container{padding:0px 0px 20px 0px;}.elementor-13507 .elementor-element.elementor-element-4a299971{--display:flex;--flex-direction:column;--container-widget-width:100%;--container-widget-height:initial;--container-widget-flex-grow:0;--container-widget-align-self:initial;--flex-wrap-mobile:wrap;--gap:20px 40px;--row-gap:20px;--column-gap:40px;border-style:none;--border-style:none;--margin-top:0px;--margin-bottom:20px;--margin-left:0px;--margin-right:0px;--padding-top:20px;--padding-bottom:20px;--padding-left:30px;--padding-right:30px;}.elementor-13507 .elementor-element.elementor-element-4a299971:not(.elementor-motion-effects-element-type-background), .elementor-13507 .elementor-element.elementor-element-4a299971 > .elementor-motion-effects-container > .elementor-motion-effects-layer{background-color:#7A7A7A0D;}.elementor-13507 .elementor-element.elementor-element-2264f626{--display:flex;--justify-content:flex-start;--gap:5px 0px;--row-gap:5px;--column-gap:0px;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-13507 .elementor-element.elementor-element-571428a8{--display:flex;--flex-direction:row;--container-widget-width:calc( ( 1 - var( --container-widget-flex-grow ) ) * 100% );--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--align-items:center;--gap:4px 8px;--row-gap:4px;--column-gap:8px;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-13507 .elementor-element.elementor-element-c9b8ac6 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );color:var( --e-global-color-accent );}.elementor-13507 .elementor-element.elementor-element-522b0f51 .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );font-weight:var( --e-global-typography-a7220b8-font-weight );line-height:var( --e-global-typography-a7220b8-line-height );color:#646464;}.elementor-13507 .elementor-element.elementor-element-241536ae{--display:flex;--flex-direction:row;--container-widget-width:calc( ( 1 - var( --container-widget-flex-grow ) ) * 100% );--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--align-items:center;--gap:4px 8px;--row-gap:4px;--column-gap:8px;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-13507 .elementor-element.elementor-element-148cd8bf .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );color:var( --e-global-color-accent );}.elementor-13507 .elementor-element.elementor-element-2294010a .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );font-weight:var( --e-global-typography-a7220b8-font-weight );line-height:var( --e-global-typography-a7220b8-line-height );color:#646464;}.elementor-13507 .elementor-element.elementor-element-392a579f{--display:flex;--flex-direction:row;--container-widget-width:calc( ( 1 - var( --container-widget-flex-grow ) ) * 100% );--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--align-items:center;--gap:4px 8px;--row-gap:4px;--column-gap:8px;--flex-wrap:wrap;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-13507 .elementor-element.elementor-element-31655606 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );color:var( --e-global-color-accent );}.elementor-13507 .elementor-element.elementor-element-34dd77b0 .elementor-heading-title{font-size:14px;font-weight:400;line-height:1.4em;color:#646464;}.elementor-13507 .elementor-element.elementor-element-4e9ff277{--display:flex;--flex-direction:row;--container-widget-width:calc( ( 1 - var( --container-widget-flex-grow ) ) * 100% );--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--align-items:center;--gap:4px 8px;--row-gap:4px;--column-gap:8px;--flex-wrap:wrap;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-13507 .elementor-element.elementor-element-8521b33 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );color:var( --e-global-color-accent );}.elementor-13507 .elementor-element.elementor-element-5bb74bd8 .elementor-heading-title{font-size:14px;font-weight:400;line-height:1.4em;color:#646464;}.elementor-13507 .elementor-element.elementor-element-67254483{--display:flex;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-13507 .elementor-element.elementor-element-33cb564e{--display:flex;--margin-top:20px;--margin-bottom:0px;--margin-left:0px;--margin-right:0px;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-13507 .elementor-element.elementor-element-4679cddc .elementor-button{background-color:var( --e-global-color-9f14806 );font-weight:500;fill:var( --e-global-color-primary );color:var( --e-global-color-primary );border-style:solid;border-width:1px 1px 1px 1px;}.elementor-13507 .elementor-element.elementor-element-4679cddc .elementor-button:hover, .elementor-13507 .elementor-element.elementor-element-4679cddc .elementor-button:focus{background-color:var( --e-global-color-primary );color:var( --e-global-color-9f14806 );}.elementor-13507 .elementor-element.elementor-element-4679cddc .elementor-button:hover svg, .elementor-13507 .elementor-element.elementor-element-4679cddc .elementor-button:focus svg{fill:var( --e-global-color-9f14806 );}.elementor-13507 .elementor-element.elementor-element-41955f1d .elementor-button{background-color:var( --e-global-color-9f14806 );font-weight:500;fill:var( --e-global-color-primary );color:var( --e-global-color-primary );border-style:solid;border-width:1px 1px 1px 1px;}.elementor-13507 .elementor-element.elementor-element-41955f1d .elementor-button:hover, .elementor-13507 .elementor-element.elementor-element-41955f1d .elementor-button:focus{background-color:var( --e-global-color-primary );color:var( --e-global-color-9f14806 );}.elementor-13507 .elementor-element.elementor-element-41955f1d .elementor-button:hover svg, .elementor-13507 .elementor-element.elementor-element-41955f1d .elementor-button:focus svg{fill:var( --e-global-color-9f14806 );}.elementor-13507 .elementor-element.elementor-element-67f1d66d{--display:flex;--flex-direction:row;--container-widget-width:calc( ( 1 - var( --container-widget-flex-grow ) ) * 100% );--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--align-items:center;--gap:10px 10px;--row-gap:10px;--column-gap:10px;--padding-top:30px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-13507 .elementor-element.elementor-element-9c6d187 > .elementor-widget-container{padding:5px 5px 5px 5px;border-style:solid;border-width:1px 1px 1px 1px;border-color:#4747475E;border-radius:46px 46px 46px 46px;}.elementor-13507 .elementor-element.elementor-element-59554da0 .elementor-icon-box-wrapper{text-align:start;}.elementor-13507 .elementor-element.elementor-element-59554da0 .elementor-icon-box-title{margin-block-end:0px;}.elementor-13507 .elementor-element.elementor-element-59554da0 .elementor-icon-box-title, .elementor-13507 .elementor-element.elementor-element-59554da0 .elementor-icon-box-title a{font-size:13px;}.elementor-13507 .elementor-element.elementor-element-59554da0 .elementor-icon-box-description{font-size:14px;line-height:15px;}@media(max-width:1366px){.elementor-13507 .elementor-element.elementor-element-c9b8ac6 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-13507 .elementor-element.elementor-element-522b0f51 .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );line-height:var( --e-global-typography-a7220b8-line-height );}.elementor-13507 .elementor-element.elementor-element-148cd8bf .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-13507 .elementor-element.elementor-element-2294010a .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );line-height:var( --e-global-typography-a7220b8-line-height );}.elementor-13507 .elementor-element.elementor-element-31655606 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-13507 .elementor-element.elementor-element-8521b33 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}}@media(max-width:1200px){.elementor-13507 .elementor-element.elementor-element-571428a8{--flex-direction:row;--container-widget-width:initial;--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--gap:0px 8px;--row-gap:0px;--column-gap:8px;--flex-wrap:wrap;}.elementor-13507 .elementor-element.elementor-element-241536ae{--flex-direction:row;--container-widget-width:initial;--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--gap:0px 8px;--row-gap:0px;--column-gap:8px;--flex-wrap:wrap;}.elementor-13507 .elementor-element.elementor-element-392a579f{--flex-direction:row;--container-widget-width:initial;--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--gap:0px 8px;--row-gap:0px;--column-gap:8px;--flex-wrap:wrap;}.elementor-13507 .elementor-element.elementor-element-4e9ff277{--flex-direction:row;--container-widget-width:initial;--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--gap:0px 8px;--row-gap:0px;--column-gap:8px;--flex-wrap:wrap;}}@media(max-width:1024px){.elementor-13507 .elementor-element.elementor-element-c9b8ac6 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-13507 .elementor-element.elementor-element-522b0f51 .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );line-height:var( --e-global-typography-a7220b8-line-height );}.elementor-13507 .elementor-element.elementor-element-148cd8bf .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-13507 .elementor-element.elementor-element-2294010a .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );line-height:var( --e-global-typography-a7220b8-line-height );}.elementor-13507 .elementor-element.elementor-element-31655606 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-13507 .elementor-element.elementor-element-8521b33 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}}@media(max-width:767px){.elementor-13507 .elementor-element.elementor-element-c9b8ac6 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-13507 .elementor-element.elementor-element-522b0f51 .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );line-height:var( --e-global-typography-a7220b8-line-height );}.elementor-13507 .elementor-element.elementor-element-148cd8bf .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-13507 .elementor-element.elementor-element-2294010a .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );line-height:var( --e-global-typography-a7220b8-line-height );}.elementor-13507 .elementor-element.elementor-element-31655606 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-13507 .elementor-element.elementor-element-8521b33 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}}</style>							<content:encoded><![CDATA[		<div data-elementor-type="wp-post" data-elementor-id="13507" class="elementor elementor-13507" data-elementor-post-type="post">
				<div class="elementor-element elementor-element-3ce7a18b e-flex e-con-boxed e-con e-parent" data-id="3ce7a18b" data-element_type="container" data-e-type="container">
					<div class="e-con-inner">
				<div class="elementor-element elementor-element-658f317a elementor-widget elementor-widget-heading" data-id="658f317a" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h2 class="elementor-heading-title elementor-size-default">ASCO 2026: Avances en Cáncer de Páncreas</h2>				</div>
				</div>
					</div>
				</div>
		<div class="elementor-element elementor-element-4a299971 e-con-full e-flex e-con e-child" data-id="4a299971" data-element_type="container" data-e-type="container" data-settings="{&quot;background_background&quot;:&quot;classic&quot;}">
		<div class="elementor-element elementor-element-2264f626 e-con-full e-flex e-con e-child" data-id="2264f626" data-element_type="container" data-e-type="container">
		<div class="elementor-element elementor-element-571428a8 e-con-full e-flex e-con e-child" data-id="571428a8" data-element_type="container" data-e-type="container">
				<div class="elementor-element elementor-element-c9b8ac6 elementor-widget elementor-widget-heading" data-id="c9b8ac6" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h5 class="elementor-heading-title elementor-size-default">Edición:</h5>				</div>
				</div>
				<div class="elementor-element elementor-element-522b0f51 elementor-widget elementor-widget-heading" data-id="522b0f51" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<p class="elementor-heading-title elementor-size-default">Publicación científica 2026</p>				</div>
				</div>
				</div>
		<div class="elementor-element elementor-element-241536ae e-con-full e-flex e-con e-child" data-id="241536ae" data-element_type="container" data-e-type="container">
				<div class="elementor-element elementor-element-148cd8bf elementor-widget elementor-widget-heading" data-id="148cd8bf" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h4 class="elementor-heading-title elementor-size-default">Fecha:</h4>				</div>
				</div>
				<div class="elementor-element elementor-element-2294010a elementor-widget elementor-widget-heading" data-id="2294010a" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<p class="elementor-heading-title elementor-size-default">31 de julio  2026</p>				</div>
				</div>
				</div>
		<div class="elementor-element elementor-element-392a579f e-con-full e-flex e-con e-child" data-id="392a579f" data-element_type="container" data-e-type="container">
				<div class="elementor-element elementor-element-31655606 elementor-widget elementor-widget-heading" data-id="31655606" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h4 class="elementor-heading-title elementor-size-default">Autores:</h4>				</div>
				</div>
				<div class="elementor-element elementor-element-34dd77b0 elementor-widget elementor-widget-heading" data-id="34dd77b0" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<p class="elementor-heading-title elementor-size-default">O'Reilly EM, Wainberg ZA, Hendifar AE, Borad MJ, Pietrantonio F, Pant S, Hammel P, Cremolini C, Manji GA, Oberstein PE, Garrido-Laguna I, Springfeld C, Azad NS, Ueno M, Chui SY, Zhang Y, Patel H, Lee Y, Salman Z, Wolpin BM.</p>				</div>
				</div>
				</div>
		<div class="elementor-element elementor-element-4e9ff277 e-con-full e-flex e-con e-child" data-id="4e9ff277" data-element_type="container" data-e-type="container">
				<div class="elementor-element elementor-element-8521b33 elementor-widget elementor-widget-heading" data-id="8521b33" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h4 class="elementor-heading-title elementor-size-default">Autor de la revisión:</h4>				</div>
				</div>
				<div class="elementor-element elementor-element-5bb74bd8 elementor-widget elementor-widget-heading" data-id="5bb74bd8" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<p class="elementor-heading-title elementor-size-default">Miguel Berzosa Sánchez. Hospital Arnau de Vilanova, Valencia (Miembro de la Asamblea General del Grupo TTD)</p>				</div>
				</div>
				</div>
				</div>
				</div>
		<div class="elementor-element elementor-element-67254483 e-flex e-con-boxed e-con e-parent" data-id="67254483" data-element_type="container" data-e-type="container">
					<div class="e-con-inner">
				<div class="elementor-element elementor-element-71cc5159 elementor-widget elementor-widget-text-editor" data-id="71cc5159" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>El ensayo fase III RASolute 302 evalúa daraxonrasib frente a quimioterapia en 500 pacientes con cáncer de páncreas metastásico previamente tratado y muestra resultados sin precedentes: en la población con mutación RAS G12 (91,8%), el fármaco duplicó la supervivencia global (13,2 vs 6,6 meses; HR 0,40; p&lt;0,001), mejoró la SLP (7,3 vs 3,5 meses; HR 0,45) y triplicó las respuestas (33,2% vs 11,8%). También retrasó el deterioro clínico por dolor. Su perfil de seguridad fue favorable, con eventos leves (rash, diarrea) y menor tasa de interrupción (1,2% vs 11,2%), aunque se registró un caso de neumonitis letal.</p><p><strong>Conclusiones: </strong></p><p>• Eficacia histórica: Daraxonrasib duplica la SG (13,2 vs 6,6 m), mejora la SLP y triplica respuestas en RAS G12. • Reducción del 60% del riesgo de muerte (HR 0,40).</p><p>• Calidad de vida: Retrasa el deterioro clínico por dolor</p><p>• Seguridad: Perfil favorable (rash/diarrea) y baja interrupción (1,2% vs 11,2%). </p><p>Impacto: Nuevo estándar en 2ª línea.</p>								</div>
				</div>
					</div>
				</div>
		<div class="elementor-element elementor-element-33cb564e e-flex e-con-boxed e-con e-parent" data-id="33cb564e" data-element_type="container" data-e-type="container">
					<div class="e-con-inner">
				<div class="elementor-element elementor-element-4679cddc elementor-align-center elementor-widget elementor-widget-button" data-id="4679cddc" data-element_type="widget" data-e-type="widget" data-widget_type="button.default">
				<div class="elementor-widget-container">
									<div class="elementor-button-wrapper">
					<a class="elementor-button elementor-button-link elementor-size-sm" href="https://grupottd.org/articulos-comentados/daraxonrasib-or-chemotherapy-in-previously-treated-metastatic-pancreatic-cancer/">
						<span class="elementor-button-content-wrapper">
									<span class="elementor-button-text">Ver artículo comentado TTD completo</span>
					</span>
					</a>
				</div>
								</div>
				</div>
				<div class="elementor-element elementor-element-41955f1d elementor-align-center elementor-widget elementor-widget-button" data-id="41955f1d" data-element_type="widget" data-e-type="widget" data-widget_type="button.default">
				<div class="elementor-widget-container">
									<div class="elementor-button-wrapper">
					<a class="elementor-button elementor-button-link elementor-size-sm" href="https://pubmed.ncbi.nlm.nih.gov/42223072/" target="_blank">
						<span class="elementor-button-content-wrapper">
									<span class="elementor-button-text">Enlace al artículo original</span>
					</span>
					</a>
				</div>
								</div>
				</div>
					</div>
				</div>
		<div class="elementor-element elementor-element-67f1d66d e-con-full e-flex e-con e-child" data-id="67f1d66d" data-element_type="container" data-e-type="container">
				<div class="elementor-element elementor-element-9c6d187 elementor-widget elementor-widget-image" data-id="9c6d187" data-element_type="widget" data-e-type="widget" data-widget_type="image.default">
				<div class="elementor-widget-container">
															<img decoding="async" src="https://grupottd.org/wp-content/uploads/elementor/thumbs/fav_icon_TTD-r8xkio7ebt5062iunra09m8cc4544reqzr28q6uark.png" title="fav_icon_TTD" alt="fav_icon_TTD" loading="lazy" />															</div>
				</div>
				<div class="elementor-element elementor-element-59554da0 elementor-widget elementor-widget-icon-box" data-id="59554da0" data-element_type="widget" data-e-type="widget" data-widget_type="icon-box.default">
				<div class="elementor-widget-container">
							<div class="elementor-icon-box-wrapper">

			
						<div class="elementor-icon-box-content">

									<h3 class="elementor-icon-box-title">
						<span  >
							Publicado por:						</span>
					</h3>
				
									<p class="elementor-icon-box-description">
						Grupo TTD					</p>
				
			</div>
			
		</div>
						</div>
				</div>
				</div>
				</div>
		]]></content:encoded>
					
					<wfw:commentRss>https://grupottd.org/asco-2026-avances-en-cancer-de-pancreas/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Tinengotinib y la medicina personalizada en colangiocarcinoma: nuevos avances</title>
		<link>https://grupottd.org/tinengotinib-y-la-medicina-personalizada-en-colangiocarcinoma-nuevos-avances/</link>
					<comments>https://grupottd.org/tinengotinib-y-la-medicina-personalizada-en-colangiocarcinoma-nuevos-avances/#respond</comments>
		
		<dc:creator><![CDATA[Susana Rodríguez]]></dc:creator>
		<pubDate>Tue, 31 Mar 2026 06:22:05 +0000</pubDate>
				<category><![CDATA[Artículos comentados]]></category>
		<category><![CDATA[Colangiocarcinoma avanzado]]></category>
		<category><![CDATA[Ensayo clínico fase II]]></category>
		<category><![CDATA[FGFR2]]></category>
		<category><![CDATA[Fusiones/ReordenamientosFGFR2]]></category>
		<category><![CDATA[Hiperfosfatemia]]></category>
		<category><![CDATA[Inhibidor multiquinasa]]></category>
		<category><![CDATA[Medicina personalizada]]></category>
		<category><![CDATA[Resistencia a inhibidores FGFR]]></category>
		<category><![CDATA[Terapia dirigida]]></category>
		<category><![CDATA[Tinengotinib]]></category>
		<guid isPermaLink="false">https://grupottd.org/?p=12751</guid>

					<description><![CDATA[Ensayo fase II multicéntrico y multicohorte evaluó tinengotinib, inhibidor multiquinasa de FGFR2, VEGFRs, JAK1-2, CSF1R y Aurora quinasa, en 55 pacientes con colangiocarcinoma avanzado tras al menos una línea de tratamiento. Se incluyeron pacientes con y sin alteraciones de FGFR (76% vs 24%), algunos con tratamiento previo con inhibidores de FGFR2. Objetivo principal: TRO por cohorte (6-30%). Efectos secundarios más frecuentes: hipertensión 64%, diarrea 47%. Se realizo de forma complementaria un estudio de comutaciones destacando TP53 como la más frecuente.]]></description>
			<style id="elementor-post-12751">.elementor-12751 .elementor-element.elementor-element-3ce7a18b{--display:flex;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-12751 .elementor-element.elementor-element-658f317a > .elementor-widget-container{padding:0px 0px 20px 0px;}.elementor-12751 .elementor-element.elementor-element-4a299971{--display:flex;--flex-direction:column;--container-widget-width:100%;--container-widget-height:initial;--container-widget-flex-grow:0;--container-widget-align-self:initial;--flex-wrap-mobile:wrap;--gap:20px 40px;--row-gap:20px;--column-gap:40px;border-style:none;--border-style:none;--margin-top:0px;--margin-bottom:20px;--margin-left:0px;--margin-right:0px;--padding-top:20px;--padding-bottom:20px;--padding-left:30px;--padding-right:30px;}.elementor-12751 .elementor-element.elementor-element-4a299971:not(.elementor-motion-effects-element-type-background), .elementor-12751 .elementor-element.elementor-element-4a299971 > .elementor-motion-effects-container > .elementor-motion-effects-layer{background-color:#7A7A7A0D;}.elementor-12751 .elementor-element.elementor-element-2264f626{--display:flex;--justify-content:flex-start;--gap:5px 0px;--row-gap:5px;--column-gap:0px;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-12751 .elementor-element.elementor-element-571428a8{--display:flex;--flex-direction:row;--container-widget-width:calc( ( 1 - var( --container-widget-flex-grow ) ) * 100% );--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--align-items:center;--gap:4px 8px;--row-gap:4px;--column-gap:8px;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-12751 .elementor-element.elementor-element-c9b8ac6 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );color:var( --e-global-color-accent );}.elementor-12751 .elementor-element.elementor-element-522b0f51 .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );font-weight:var( --e-global-typography-a7220b8-font-weight );line-height:var( --e-global-typography-a7220b8-line-height );color:#646464;}.elementor-12751 .elementor-element.elementor-element-241536ae{--display:flex;--flex-direction:row;--container-widget-width:calc( ( 1 - var( --container-widget-flex-grow ) ) * 100% );--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--align-items:center;--gap:4px 8px;--row-gap:4px;--column-gap:8px;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-12751 .elementor-element.elementor-element-148cd8bf .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );color:var( --e-global-color-accent );}.elementor-12751 .elementor-element.elementor-element-2294010a .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );font-weight:var( --e-global-typography-a7220b8-font-weight );line-height:var( --e-global-typography-a7220b8-line-height );color:#646464;}.elementor-12751 .elementor-element.elementor-element-392a579f{--display:flex;--flex-direction:row;--container-widget-width:calc( ( 1 - var( --container-widget-flex-grow ) ) * 100% );--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--align-items:center;--gap:4px 8px;--row-gap:4px;--column-gap:8px;--flex-wrap:wrap;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-12751 .elementor-element.elementor-element-31655606 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );color:var( --e-global-color-accent );}.elementor-12751 .elementor-element.elementor-element-34dd77b0 .elementor-heading-title{font-size:14px;font-weight:400;line-height:1.4em;color:#646464;}.elementor-12751 .elementor-element.elementor-element-4e9ff277{--display:flex;--flex-direction:row;--container-widget-width:calc( ( 1 - var( --container-widget-flex-grow ) ) * 100% );--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--align-items:center;--gap:4px 8px;--row-gap:4px;--column-gap:8px;--flex-wrap:wrap;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-12751 .elementor-element.elementor-element-8521b33 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );color:var( --e-global-color-accent );}.elementor-12751 .elementor-element.elementor-element-5bb74bd8 .elementor-heading-title{font-size:14px;font-weight:400;line-height:1.4em;color:#646464;}.elementor-12751 .elementor-element.elementor-element-67254483{--display:flex;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-12751 .elementor-element.elementor-element-33cb564e{--display:flex;--margin-top:20px;--margin-bottom:0px;--margin-left:0px;--margin-right:0px;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-12751 .elementor-element.elementor-element-4679cddc .elementor-button{background-color:var( --e-global-color-9f14806 );font-weight:500;fill:var( --e-global-color-primary );color:var( --e-global-color-primary );border-style:solid;border-width:1px 1px 1px 1px;}.elementor-12751 .elementor-element.elementor-element-4679cddc .elementor-button:hover, .elementor-12751 .elementor-element.elementor-element-4679cddc .elementor-button:focus{background-color:var( --e-global-color-primary );color:var( --e-global-color-9f14806 );}.elementor-12751 .elementor-element.elementor-element-4679cddc .elementor-button:hover svg, .elementor-12751 .elementor-element.elementor-element-4679cddc .elementor-button:focus svg{fill:var( --e-global-color-9f14806 );}.elementor-12751 .elementor-element.elementor-element-41955f1d .elementor-button{background-color:var( --e-global-color-9f14806 );font-weight:500;fill:var( --e-global-color-primary );color:var( --e-global-color-primary );border-style:solid;border-width:1px 1px 1px 1px;}.elementor-12751 .elementor-element.elementor-element-41955f1d .elementor-button:hover, .elementor-12751 .elementor-element.elementor-element-41955f1d .elementor-button:focus{background-color:var( --e-global-color-primary );color:var( --e-global-color-9f14806 );}.elementor-12751 .elementor-element.elementor-element-41955f1d .elementor-button:hover svg, .elementor-12751 .elementor-element.elementor-element-41955f1d .elementor-button:focus svg{fill:var( --e-global-color-9f14806 );}.elementor-12751 .elementor-element.elementor-element-67f1d66d{--display:flex;--flex-direction:row;--container-widget-width:calc( ( 1 - var( --container-widget-flex-grow ) ) * 100% );--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--align-items:center;--gap:10px 10px;--row-gap:10px;--column-gap:10px;--padding-top:30px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-12751 .elementor-element.elementor-element-9c6d187 > .elementor-widget-container{padding:5px 5px 5px 5px;border-style:solid;border-width:1px 1px 1px 1px;border-color:#4747475E;border-radius:46px 46px 46px 46px;}.elementor-12751 .elementor-element.elementor-element-59554da0 .elementor-icon-box-wrapper{text-align:start;}.elementor-12751 .elementor-element.elementor-element-59554da0 .elementor-icon-box-title{margin-block-end:0px;}.elementor-12751 .elementor-element.elementor-element-59554da0 .elementor-icon-box-title, .elementor-12751 .elementor-element.elementor-element-59554da0 .elementor-icon-box-title a{font-size:13px;}.elementor-12751 .elementor-element.elementor-element-59554da0 .elementor-icon-box-description{font-size:14px;line-height:15px;}@media(max-width:1366px){.elementor-12751 .elementor-element.elementor-element-c9b8ac6 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-12751 .elementor-element.elementor-element-522b0f51 .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );line-height:var( --e-global-typography-a7220b8-line-height );}.elementor-12751 .elementor-element.elementor-element-148cd8bf .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-12751 .elementor-element.elementor-element-2294010a .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );line-height:var( --e-global-typography-a7220b8-line-height );}.elementor-12751 .elementor-element.elementor-element-31655606 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-12751 .elementor-element.elementor-element-8521b33 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}}@media(max-width:1200px){.elementor-12751 .elementor-element.elementor-element-571428a8{--flex-direction:row;--container-widget-width:initial;--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--gap:0px 8px;--row-gap:0px;--column-gap:8px;--flex-wrap:wrap;}.elementor-12751 .elementor-element.elementor-element-241536ae{--flex-direction:row;--container-widget-width:initial;--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--gap:0px 8px;--row-gap:0px;--column-gap:8px;--flex-wrap:wrap;}.elementor-12751 .elementor-element.elementor-element-392a579f{--flex-direction:row;--container-widget-width:initial;--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--gap:0px 8px;--row-gap:0px;--column-gap:8px;--flex-wrap:wrap;}.elementor-12751 .elementor-element.elementor-element-4e9ff277{--flex-direction:row;--container-widget-width:initial;--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--gap:0px 8px;--row-gap:0px;--column-gap:8px;--flex-wrap:wrap;}}@media(max-width:1024px){.elementor-12751 .elementor-element.elementor-element-c9b8ac6 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-12751 .elementor-element.elementor-element-522b0f51 .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );line-height:var( --e-global-typography-a7220b8-line-height );}.elementor-12751 .elementor-element.elementor-element-148cd8bf .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-12751 .elementor-element.elementor-element-2294010a .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );line-height:var( --e-global-typography-a7220b8-line-height );}.elementor-12751 .elementor-element.elementor-element-31655606 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-12751 .elementor-element.elementor-element-8521b33 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}}@media(max-width:767px){.elementor-12751 .elementor-element.elementor-element-c9b8ac6 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-12751 .elementor-element.elementor-element-522b0f51 .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );line-height:var( --e-global-typography-a7220b8-line-height );}.elementor-12751 .elementor-element.elementor-element-148cd8bf .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-12751 .elementor-element.elementor-element-2294010a .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );line-height:var( --e-global-typography-a7220b8-line-height );}.elementor-12751 .elementor-element.elementor-element-31655606 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-12751 .elementor-element.elementor-element-8521b33 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}}</style>							<content:encoded><![CDATA[		<div data-elementor-type="wp-post" data-elementor-id="12751" class="elementor elementor-12751" data-elementor-post-type="post">
				<div class="elementor-element elementor-element-3ce7a18b e-flex e-con-boxed e-con e-parent" data-id="3ce7a18b" data-element_type="container" data-e-type="container">
					<div class="e-con-inner">
				<div class="elementor-element elementor-element-658f317a elementor-widget elementor-widget-heading" data-id="658f317a" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h2 class="elementor-heading-title elementor-size-default">Tinengotinib y la medicina personalizada en colangiocarcinoma: nuevos avances</h2>				</div>
				</div>
					</div>
				</div>
		<div class="elementor-element elementor-element-4a299971 e-con-full e-flex e-con e-child" data-id="4a299971" data-element_type="container" data-e-type="container" data-settings="{&quot;background_background&quot;:&quot;classic&quot;}">
		<div class="elementor-element elementor-element-2264f626 e-con-full e-flex e-con e-child" data-id="2264f626" data-element_type="container" data-e-type="container">
		<div class="elementor-element elementor-element-571428a8 e-con-full e-flex e-con e-child" data-id="571428a8" data-element_type="container" data-e-type="container">
				<div class="elementor-element elementor-element-c9b8ac6 elementor-widget elementor-widget-heading" data-id="c9b8ac6" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h5 class="elementor-heading-title elementor-size-default">Edición:</h5>				</div>
				</div>
				<div class="elementor-element elementor-element-522b0f51 elementor-widget elementor-widget-heading" data-id="522b0f51" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<p class="elementor-heading-title elementor-size-default">Publicación científica 2026</p>				</div>
				</div>
				</div>
		<div class="elementor-element elementor-element-241536ae e-con-full e-flex e-con e-child" data-id="241536ae" data-element_type="container" data-e-type="container">
				<div class="elementor-element elementor-element-148cd8bf elementor-widget elementor-widget-heading" data-id="148cd8bf" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h4 class="elementor-heading-title elementor-size-default">Fecha:</h4>				</div>
				</div>
				<div class="elementor-element elementor-element-2294010a elementor-widget elementor-widget-heading" data-id="2294010a" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<p class="elementor-heading-title elementor-size-default">31 de marzo de 2026</p>				</div>
				</div>
				</div>
		<div class="elementor-element elementor-element-392a579f e-con-full e-flex e-con e-child" data-id="392a579f" data-element_type="container" data-e-type="container">
				<div class="elementor-element elementor-element-31655606 elementor-widget elementor-widget-heading" data-id="31655606" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h4 class="elementor-heading-title elementor-size-default">Autores:</h4>				</div>
				</div>
				<div class="elementor-element elementor-element-34dd77b0 elementor-widget elementor-widget-heading" data-id="34dd77b0" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<p class="elementor-heading-title elementor-size-default">Milind Javle, Christos Fountzilas, Chih-Yi Liao, Meredith Pelster, Daneng Li, Dustin Deming, Vaibhav Sahai, Lionel Kankeu Fonkoua, Allen Cohn, Parvez Mantry, Donald Richards, Edwin Kingsley, Frank Wu, Peng Peng, Katie Hennessy, Hui Wang, Caixia Sun, Shumao Ni, Jean Fan, Amit Mahipal</p>				</div>
				</div>
				</div>
		<div class="elementor-element elementor-element-4e9ff277 e-con-full e-flex e-con e-child" data-id="4e9ff277" data-element_type="container" data-e-type="container">
				<div class="elementor-element elementor-element-8521b33 elementor-widget elementor-widget-heading" data-id="8521b33" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h4 class="elementor-heading-title elementor-size-default">Autor de la revisión:</h4>				</div>
				</div>
				<div class="elementor-element elementor-element-5bb74bd8 elementor-widget elementor-widget-heading" data-id="5bb74bd8" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<p class="elementor-heading-title elementor-size-default">Marta Amann. Hospital Clínico San Carlos de Madrid. (Miembro de la Asamblea General del Grupo TTD)</p>				</div>
				</div>
				</div>
				</div>
				</div>
		<div class="elementor-element elementor-element-67254483 e-flex e-con-boxed e-con e-parent" data-id="67254483" data-element_type="container" data-e-type="container">
					<div class="e-con-inner">
				<div class="elementor-element elementor-element-71cc5159 elementor-widget elementor-widget-text-editor" data-id="71cc5159" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>Ensayo fase II multicéntrico y multicohorte evaluó tinengotinib, inhibidor multiquinasa de FGFR2, VEGFRs, JAK1-2, CSF1R y Aurora quinasa, en 55 pacientes con colangiocarcinoma avanzado tras al menos una línea de tratamiento. Se incluyeron pacientes con y sin alteraciones de FGFR (76% vs 24%), algunos con tratamiento previo con inhibidores de FGFR2. Objetivo principal: TRO por cohorte (6-30%). Efectos secundarios más frecuentes: hipertensión 64%, diarrea 47%. Se realizo de forma complementaria un estudio de comutaciones destacando TP53 como la más frecuente.</p>								</div>
				</div>
					</div>
				</div>
		<div class="elementor-element elementor-element-33cb564e e-flex e-con-boxed e-con e-parent" data-id="33cb564e" data-element_type="container" data-e-type="container">
					<div class="e-con-inner">
				<div class="elementor-element elementor-element-4679cddc elementor-align-center elementor-widget elementor-widget-button" data-id="4679cddc" data-element_type="widget" data-e-type="widget" data-widget_type="button.default">
				<div class="elementor-widget-container">
									<div class="elementor-button-wrapper">
					<a class="elementor-button elementor-button-link elementor-size-sm" href="https://grupottd.org/articulos-comentados/tinengotinib-for-adults-with-advanced-or-metastatic-cholangiocarcinoma-a-multicentre-open-label-phase-2-trial/">
						<span class="elementor-button-content-wrapper">
									<span class="elementor-button-text">Ver artículo comentado TTD completo</span>
					</span>
					</a>
				</div>
								</div>
				</div>
				<div class="elementor-element elementor-element-41955f1d elementor-align-center elementor-widget elementor-widget-button" data-id="41955f1d" data-element_type="widget" data-e-type="widget" data-widget_type="button.default">
				<div class="elementor-widget-container">
									<div class="elementor-button-wrapper">
					<a class="elementor-button elementor-button-link elementor-size-sm" href="https://pubmed.ncbi.nlm.nih.gov/41349554/" target="_blank">
						<span class="elementor-button-content-wrapper">
									<span class="elementor-button-text">Enlace al artículo original</span>
					</span>
					</a>
				</div>
								</div>
				</div>
					</div>
				</div>
		<div class="elementor-element elementor-element-67f1d66d e-con-full e-flex e-con e-child" data-id="67f1d66d" data-element_type="container" data-e-type="container">
				<div class="elementor-element elementor-element-9c6d187 elementor-widget elementor-widget-image" data-id="9c6d187" data-element_type="widget" data-e-type="widget" data-widget_type="image.default">
				<div class="elementor-widget-container">
															<img decoding="async" src="https://grupottd.org/wp-content/uploads/elementor/thumbs/fav_icon_TTD-r8xkio7ebt5062iunra09m8cc4544reqzr28q6uark.png" title="fav_icon_TTD" alt="fav_icon_TTD" loading="lazy" />															</div>
				</div>
				<div class="elementor-element elementor-element-59554da0 elementor-widget elementor-widget-icon-box" data-id="59554da0" data-element_type="widget" data-e-type="widget" data-widget_type="icon-box.default">
				<div class="elementor-widget-container">
							<div class="elementor-icon-box-wrapper">

			
						<div class="elementor-icon-box-content">

									<h3 class="elementor-icon-box-title">
						<span  >
							Publicado por:						</span>
					</h3>
				
									<p class="elementor-icon-box-description">
						Grupo TTD					</p>
				
			</div>
			
		</div>
						</div>
				</div>
				</div>
				</div>
		]]></content:encoded>
					
					<wfw:commentRss>https://grupottd.org/tinengotinib-y-la-medicina-personalizada-en-colangiocarcinoma-nuevos-avances/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Cáncer gástrico HER2-positivo: resultados del estudio fase III KC-WISE</title>
		<link>https://grupottd.org/cancer-gastrico-her2-positivo-resultados-del-estudio-fase-iii-kc-wise/</link>
					<comments>https://grupottd.org/cancer-gastrico-her2-positivo-resultados-del-estudio-fase-iii-kc-wise/#respond</comments>
		
		<dc:creator><![CDATA[Susana Rodríguez]]></dc:creator>
		<pubDate>Thu, 12 Mar 2026 09:27:50 +0000</pubDate>
				<category><![CDATA[Artículos comentados]]></category>
		<category><![CDATA[Anbenitamab]]></category>
		<category><![CDATA[Anticuerpos biespecíficos]]></category>
		<category><![CDATA[Cáncer gástrico]]></category>
		<category><![CDATA[Ensayo fase III]]></category>
		<category><![CDATA[HER2 positivo]]></category>
		<category><![CDATA[Oncología digestiva]]></category>
		<category><![CDATA[Post-trastuzumab]]></category>
		<category><![CDATA[Segunda línea]]></category>
		<category><![CDATA[Terapia dirigida]]></category>
		<category><![CDATA[Unión gastroesofágica]]></category>
		<guid isPermaLink="false">https://grupottd.org/?p=12607</guid>

					<description><![CDATA[El ensayo fase III KC-WISE evaluó la eficacia y seguridad de anbenitamab, un anticuerpo biespecífico anti-HER2, en combinación con quimioterapia en pacientes con adenocarcinoma gástrico o de la unión gastroesofágica HER2-positivo previamente tratados con trastuzumab. En un análisis preliminar preespecificado, la combinación demostró mejoras significativas en supervivencia libre de progresión, supervivencia global y tasa de respuesta objetiva frente a quimioterapia sola, con un perfil de seguridad manejable, lo que sugiere su potencial como nueva estrategia terapéutica en este escenario clínico.]]></description>
			<style id="elementor-post-12607">.elementor-12607 .elementor-element.elementor-element-3ce7a18b{--display:flex;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-12607 .elementor-element.elementor-element-658f317a > .elementor-widget-container{padding:0px 0px 20px 0px;}.elementor-12607 .elementor-element.elementor-element-4a299971{--display:flex;--flex-direction:column;--container-widget-width:100%;--container-widget-height:initial;--container-widget-flex-grow:0;--container-widget-align-self:initial;--flex-wrap-mobile:wrap;--gap:20px 40px;--row-gap:20px;--column-gap:40px;border-style:none;--border-style:none;--margin-top:0px;--margin-bottom:20px;--margin-left:0px;--margin-right:0px;--padding-top:20px;--padding-bottom:20px;--padding-left:30px;--padding-right:30px;}.elementor-12607 .elementor-element.elementor-element-4a299971:not(.elementor-motion-effects-element-type-background), .elementor-12607 .elementor-element.elementor-element-4a299971 > .elementor-motion-effects-container > .elementor-motion-effects-layer{background-color:#7A7A7A0D;}.elementor-12607 .elementor-element.elementor-element-2264f626{--display:flex;--justify-content:flex-start;--gap:5px 0px;--row-gap:5px;--column-gap:0px;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-12607 .elementor-element.elementor-element-571428a8{--display:flex;--flex-direction:row;--container-widget-width:calc( ( 1 - var( --container-widget-flex-grow ) ) * 100% );--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--align-items:center;--gap:4px 8px;--row-gap:4px;--column-gap:8px;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-12607 .elementor-element.elementor-element-c9b8ac6 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );color:var( --e-global-color-accent );}.elementor-12607 .elementor-element.elementor-element-522b0f51 .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );font-weight:var( --e-global-typography-a7220b8-font-weight );line-height:var( --e-global-typography-a7220b8-line-height );color:#646464;}.elementor-12607 .elementor-element.elementor-element-241536ae{--display:flex;--flex-direction:row;--container-widget-width:calc( ( 1 - var( --container-widget-flex-grow ) ) * 100% );--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--align-items:center;--gap:4px 8px;--row-gap:4px;--column-gap:8px;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-12607 .elementor-element.elementor-element-148cd8bf .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );color:var( --e-global-color-accent );}.elementor-12607 .elementor-element.elementor-element-2294010a .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );font-weight:var( --e-global-typography-a7220b8-font-weight );line-height:var( --e-global-typography-a7220b8-line-height );color:#646464;}.elementor-12607 .elementor-element.elementor-element-392a579f{--display:flex;--flex-direction:row;--container-widget-width:calc( ( 1 - var( --container-widget-flex-grow ) ) * 100% );--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--align-items:center;--gap:4px 8px;--row-gap:4px;--column-gap:8px;--flex-wrap:wrap;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-12607 .elementor-element.elementor-element-31655606 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );color:var( --e-global-color-accent );}.elementor-12607 .elementor-element.elementor-element-34dd77b0 .elementor-heading-title{font-size:14px;font-weight:400;line-height:1.4em;color:#646464;}.elementor-12607 .elementor-element.elementor-element-4e9ff277{--display:flex;--flex-direction:row;--container-widget-width:calc( ( 1 - var( --container-widget-flex-grow ) ) * 100% );--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--align-items:center;--gap:4px 8px;--row-gap:4px;--column-gap:8px;--flex-wrap:wrap;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-12607 .elementor-element.elementor-element-8521b33 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );color:var( --e-global-color-accent );}.elementor-12607 .elementor-element.elementor-element-5bb74bd8 .elementor-heading-title{font-size:14px;font-weight:400;line-height:1.4em;color:#646464;}.elementor-12607 .elementor-element.elementor-element-67254483{--display:flex;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-12607 .elementor-element.elementor-element-33cb564e{--display:flex;--margin-top:20px;--margin-bottom:0px;--margin-left:0px;--margin-right:0px;--padding-top:0px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-12607 .elementor-element.elementor-element-4679cddc .elementor-button{background-color:var( --e-global-color-9f14806 );font-weight:500;fill:var( --e-global-color-primary );color:var( --e-global-color-primary );border-style:solid;border-width:1px 1px 1px 1px;}.elementor-12607 .elementor-element.elementor-element-4679cddc .elementor-button:hover, .elementor-12607 .elementor-element.elementor-element-4679cddc .elementor-button:focus{background-color:var( --e-global-color-primary );color:var( --e-global-color-9f14806 );}.elementor-12607 .elementor-element.elementor-element-4679cddc .elementor-button:hover svg, .elementor-12607 .elementor-element.elementor-element-4679cddc .elementor-button:focus svg{fill:var( --e-global-color-9f14806 );}.elementor-12607 .elementor-element.elementor-element-41955f1d .elementor-button{background-color:var( --e-global-color-9f14806 );font-weight:500;fill:var( --e-global-color-primary );color:var( --e-global-color-primary );border-style:solid;border-width:1px 1px 1px 1px;}.elementor-12607 .elementor-element.elementor-element-41955f1d .elementor-button:hover, .elementor-12607 .elementor-element.elementor-element-41955f1d .elementor-button:focus{background-color:var( --e-global-color-primary );color:var( --e-global-color-9f14806 );}.elementor-12607 .elementor-element.elementor-element-41955f1d .elementor-button:hover svg, .elementor-12607 .elementor-element.elementor-element-41955f1d .elementor-button:focus svg{fill:var( --e-global-color-9f14806 );}.elementor-12607 .elementor-element.elementor-element-67f1d66d{--display:flex;--flex-direction:row;--container-widget-width:calc( ( 1 - var( --container-widget-flex-grow ) ) * 100% );--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--align-items:center;--gap:10px 10px;--row-gap:10px;--column-gap:10px;--padding-top:30px;--padding-bottom:0px;--padding-left:0px;--padding-right:0px;}.elementor-12607 .elementor-element.elementor-element-9c6d187 > .elementor-widget-container{padding:5px 5px 5px 5px;border-style:solid;border-width:1px 1px 1px 1px;border-color:#4747475E;border-radius:46px 46px 46px 46px;}.elementor-12607 .elementor-element.elementor-element-59554da0 .elementor-icon-box-wrapper{text-align:start;}.elementor-12607 .elementor-element.elementor-element-59554da0 .elementor-icon-box-title{margin-block-end:0px;}.elementor-12607 .elementor-element.elementor-element-59554da0 .elementor-icon-box-title, .elementor-12607 .elementor-element.elementor-element-59554da0 .elementor-icon-box-title a{font-size:13px;}.elementor-12607 .elementor-element.elementor-element-59554da0 .elementor-icon-box-description{font-size:14px;line-height:15px;}@media(max-width:1366px){.elementor-12607 .elementor-element.elementor-element-c9b8ac6 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-12607 .elementor-element.elementor-element-522b0f51 .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );line-height:var( --e-global-typography-a7220b8-line-height );}.elementor-12607 .elementor-element.elementor-element-148cd8bf .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-12607 .elementor-element.elementor-element-2294010a .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );line-height:var( --e-global-typography-a7220b8-line-height );}.elementor-12607 .elementor-element.elementor-element-31655606 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-12607 .elementor-element.elementor-element-8521b33 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}}@media(max-width:1200px){.elementor-12607 .elementor-element.elementor-element-571428a8{--flex-direction:row;--container-widget-width:initial;--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--gap:0px 8px;--row-gap:0px;--column-gap:8px;--flex-wrap:wrap;}.elementor-12607 .elementor-element.elementor-element-241536ae{--flex-direction:row;--container-widget-width:initial;--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--gap:0px 8px;--row-gap:0px;--column-gap:8px;--flex-wrap:wrap;}.elementor-12607 .elementor-element.elementor-element-392a579f{--flex-direction:row;--container-widget-width:initial;--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--gap:0px 8px;--row-gap:0px;--column-gap:8px;--flex-wrap:wrap;}.elementor-12607 .elementor-element.elementor-element-4e9ff277{--flex-direction:row;--container-widget-width:initial;--container-widget-height:100%;--container-widget-flex-grow:1;--container-widget-align-self:stretch;--flex-wrap-mobile:wrap;--gap:0px 8px;--row-gap:0px;--column-gap:8px;--flex-wrap:wrap;}}@media(max-width:1024px){.elementor-12607 .elementor-element.elementor-element-c9b8ac6 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-12607 .elementor-element.elementor-element-522b0f51 .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );line-height:var( --e-global-typography-a7220b8-line-height );}.elementor-12607 .elementor-element.elementor-element-148cd8bf .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-12607 .elementor-element.elementor-element-2294010a .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );line-height:var( --e-global-typography-a7220b8-line-height );}.elementor-12607 .elementor-element.elementor-element-31655606 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-12607 .elementor-element.elementor-element-8521b33 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}}@media(max-width:767px){.elementor-12607 .elementor-element.elementor-element-c9b8ac6 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-12607 .elementor-element.elementor-element-522b0f51 .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );line-height:var( --e-global-typography-a7220b8-line-height );}.elementor-12607 .elementor-element.elementor-element-148cd8bf .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-12607 .elementor-element.elementor-element-2294010a .elementor-heading-title{font-size:var( --e-global-typography-a7220b8-font-size );line-height:var( --e-global-typography-a7220b8-line-height );}.elementor-12607 .elementor-element.elementor-element-31655606 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}.elementor-12607 .elementor-element.elementor-element-8521b33 .elementor-heading-title{font-size:var( --e-global-typography-d3d4f5c-font-size );line-height:var( --e-global-typography-d3d4f5c-line-height );}}</style>							<content:encoded><![CDATA[		<div data-elementor-type="wp-post" data-elementor-id="12607" class="elementor elementor-12607" data-elementor-post-type="post">
				<div class="elementor-element elementor-element-3ce7a18b e-flex e-con-boxed e-con e-parent" data-id="3ce7a18b" data-element_type="container" data-e-type="container">
					<div class="e-con-inner">
				<div class="elementor-element elementor-element-658f317a elementor-widget elementor-widget-heading" data-id="658f317a" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h2 class="elementor-heading-title elementor-size-default">Cáncer gástrico HER2-positivo: resultados del estudio fase III KC-WISE</h2>				</div>
				</div>
					</div>
				</div>
		<div class="elementor-element elementor-element-4a299971 e-con-full e-flex e-con e-child" data-id="4a299971" data-element_type="container" data-e-type="container" data-settings="{&quot;background_background&quot;:&quot;classic&quot;}">
		<div class="elementor-element elementor-element-2264f626 e-con-full e-flex e-con e-child" data-id="2264f626" data-element_type="container" data-e-type="container">
		<div class="elementor-element elementor-element-571428a8 e-con-full e-flex e-con e-child" data-id="571428a8" data-element_type="container" data-e-type="container">
				<div class="elementor-element elementor-element-c9b8ac6 elementor-widget elementor-widget-heading" data-id="c9b8ac6" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h5 class="elementor-heading-title elementor-size-default">Edición:</h5>				</div>
				</div>
				<div class="elementor-element elementor-element-522b0f51 elementor-widget elementor-widget-heading" data-id="522b0f51" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<p class="elementor-heading-title elementor-size-default">Publicación científica 2026</p>				</div>
				</div>
				</div>
		<div class="elementor-element elementor-element-241536ae e-con-full e-flex e-con e-child" data-id="241536ae" data-element_type="container" data-e-type="container">
				<div class="elementor-element elementor-element-148cd8bf elementor-widget elementor-widget-heading" data-id="148cd8bf" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h4 class="elementor-heading-title elementor-size-default">Fecha:</h4>				</div>
				</div>
				<div class="elementor-element elementor-element-2294010a elementor-widget elementor-widget-heading" data-id="2294010a" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<p class="elementor-heading-title elementor-size-default">12 de marzo de 2026</p>				</div>
				</div>
				</div>
		<div class="elementor-element elementor-element-392a579f e-con-full e-flex e-con e-child" data-id="392a579f" data-element_type="container" data-e-type="container">
				<div class="elementor-element elementor-element-31655606 elementor-widget elementor-widget-heading" data-id="31655606" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h4 class="elementor-heading-title elementor-size-default">Autores:</h4>				</div>
				</div>
				<div class="elementor-element elementor-element-34dd77b0 elementor-widget elementor-widget-heading" data-id="34dd77b0" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<p class="elementor-heading-title elementor-size-default">Liu R, Zhao J, Zhang R, Liu B, Liu Y, Li S, Chen Y, Yang H, Liu Z, Li Z, Qin Y, Huang M, Ba Y, Zhang H, Qu Y, Du Y, Deng T, Yang M, Hou X, Liu C, Ning F, Liu YP, Wu X, Xie Y, An Y, Zou K, She L, Xu J. </p>				</div>
				</div>
				</div>
		<div class="elementor-element elementor-element-4e9ff277 e-con-full e-flex e-con e-child" data-id="4e9ff277" data-element_type="container" data-e-type="container">
				<div class="elementor-element elementor-element-8521b33 elementor-widget elementor-widget-heading" data-id="8521b33" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<h4 class="elementor-heading-title elementor-size-default">Autor de la revisión:</h4>				</div>
				</div>
				<div class="elementor-element elementor-element-5bb74bd8 elementor-widget elementor-widget-heading" data-id="5bb74bd8" data-element_type="widget" data-e-type="widget" data-widget_type="heading.default">
				<div class="elementor-widget-container">
					<p class="elementor-heading-title elementor-size-default">Eduardo Terán Brage. Hospital Universitario Vall d`Hebron – Vall d`hebron Institute of Oncology (VHIO) (Miembro de la Asamblea General del Grupo TTD)</p>				</div>
				</div>
				</div>
				</div>
				</div>
		<div class="elementor-element elementor-element-67254483 e-flex e-con-boxed e-con e-parent" data-id="67254483" data-element_type="container" data-e-type="container">
					<div class="e-con-inner">
				<div class="elementor-element elementor-element-71cc5159 elementor-widget elementor-widget-text-editor" data-id="71cc5159" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>El ensayo fase III KC-WISE evaluó la eficacia y seguridad de anbenitamab, un anticuerpo biespecífico anti-HER2, en combinación con quimioterapia en pacientes con adenocarcinoma gástrico o de la unión gastroesofágica HER2-positivo previamente tratados con trastuzumab. En un análisis preliminar preespecificado, la combinación demostró mejoras significativas en supervivencia libre de progresión, supervivencia global y tasa de respuesta objetiva frente a quimioterapia sola, con un perfil de seguridad manejable, lo que sugiere su potencial como nueva estrategia terapéutica en este escenario clínico.</p>								</div>
				</div>
					</div>
				</div>
		<div class="elementor-element elementor-element-33cb564e e-flex e-con-boxed e-con e-parent" data-id="33cb564e" data-element_type="container" data-e-type="container">
					<div class="e-con-inner">
				<div class="elementor-element elementor-element-4679cddc elementor-align-center elementor-widget elementor-widget-button" data-id="4679cddc" data-element_type="widget" data-e-type="widget" data-widget_type="button.default">
				<div class="elementor-widget-container">
									<div class="elementor-button-wrapper">
					<a class="elementor-button elementor-button-link elementor-size-sm" href="https://grupottd.org/articulos-comentados/anbenitamab-in-previously-treated-her2-positive-gastric-cancer-kc-wise-prespecified-interim-analysis-of-a-randomized-phase-iii-clinical-trial/">
						<span class="elementor-button-content-wrapper">
									<span class="elementor-button-text">Ver artículo comentado TTD completo</span>
					</span>
					</a>
				</div>
								</div>
				</div>
				<div class="elementor-element elementor-element-41955f1d elementor-align-center elementor-widget elementor-widget-button" data-id="41955f1d" data-element_type="widget" data-e-type="widget" data-widget_type="button.default">
				<div class="elementor-widget-container">
									<div class="elementor-button-wrapper">
					<a class="elementor-button elementor-button-link elementor-size-sm" href="https://pubmed.ncbi.nlm.nih.gov/41571045/" target="_blank">
						<span class="elementor-button-content-wrapper">
									<span class="elementor-button-text">Enlace al artículo original</span>
					</span>
					</a>
				</div>
								</div>
				</div>
					</div>
				</div>
		<div class="elementor-element elementor-element-67f1d66d e-con-full e-flex e-con e-child" data-id="67f1d66d" data-element_type="container" data-e-type="container">
				<div class="elementor-element elementor-element-9c6d187 elementor-widget elementor-widget-image" data-id="9c6d187" data-element_type="widget" data-e-type="widget" data-widget_type="image.default">
				<div class="elementor-widget-container">
															<img decoding="async" src="https://grupottd.org/wp-content/uploads/elementor/thumbs/fav_icon_TTD-r8xkio7ebt5062iunra09m8cc4544reqzr28q6uark.png" title="fav_icon_TTD" alt="fav_icon_TTD" loading="lazy" />															</div>
				</div>
				<div class="elementor-element elementor-element-59554da0 elementor-widget elementor-widget-icon-box" data-id="59554da0" data-element_type="widget" data-e-type="widget" data-widget_type="icon-box.default">
				<div class="elementor-widget-container">
							<div class="elementor-icon-box-wrapper">

			
						<div class="elementor-icon-box-content">

									<h3 class="elementor-icon-box-title">
						<span  >
							Publicado por:						</span>
					</h3>
				
									<p class="elementor-icon-box-description">
						Grupo TTD					</p>
				
			</div>
			
		</div>
						</div>
				</div>
				</div>
				</div>
		]]></content:encoded>
					
					<wfw:commentRss>https://grupottd.org/cancer-gastrico-her2-positivo-resultados-del-estudio-fase-iii-kc-wise/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
	</channel>
</rss>
